Multiple Myeloma Clinical Trial

Patient and Care Partner Experiences Living With Multiple Myeloma (PaCE-MM)

Summary

This research study is explore the impact over time of multiple myeloma and its associated treatments on the physical and cognitive function and quality of life of patients and their care partners and how these impacts affect the overall illness experience.

View Full Description

Full Description

This study aims to identify the factors, for example, age, race, sex, education, household income, clinical or other geriatric conditions such as depression, anxiety, or lack of social support that can predict those most likely to experience changes in physical and cognitive function and quality of life. Furthermore, patients and care partners experienced challenges, because of multiple myeloma and its associated treatments, will be studied using semi-structured interviews.

Patients will complete baseline geriatric assessments and a 30-45-minute cognitive test, and both will be reassessed in 3 months intervals. The geriatric assessment is primarily patient-reported surveys and involves a multi-domain evaluation of a patient's functional status (i.e., their ability to live independently at home and in the community), co-morbid medical conditions, cognition, psychological status, social functioning and support, medications, and nutritional status. Care Partners will be asked to complete baseline surveys that will also assess their well-being and ability to function at home.

To provide a more comprehensive understanding of the myeloma-related experiences a subset of patients and their care partners will be asked to participate in a baseline interview repeated over time to understand how the disease and its treatments shape the experiences.

Duration of Subject Participation: 6 months

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patients must meet the following inclusion criteria to participate in this study:

Aged ≥55
New myeloma diagnosis as defined by the International Myeloma Working Group, does not have another non-myeloma plasma cell disorder such as POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma cell disorder, skin changes) or amyloidosis.
Starting systemic treatment.
Able to understand and speak in English.
Able to provide informed consent to participate.

Care Partners must meet the following inclusion criteria to participate in this study

Aged ≥18.
Able to understand and speak in English.
Able to provide informed consent to participate.
Be a care partner for a patient with multiple myeloma and is also enrolled in the assessment portion of this study.
Willing and able to participate in semi-structured interviews.

Exclusion Criteria:

All participants meeting any of the following exclusion criteria at enrollment will be excluded from the study: Inability to read and speak English.
Dementia altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent.

Study is for people with:

Multiple Myeloma

Estimated Enrollment:

64

Study ID:

NCT05276622

Recruitment Status:

Terminated

Sponsor:

UNC Lineberger Comprehensive Cancer Center

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Lineberger Comprehensive Cancer Center
Chapel Hill North Carolina, 27514, United States

How clear is this clinincal trial information?

Study is for people with:

Multiple Myeloma

Estimated Enrollment:

64

Study ID:

NCT05276622

Recruitment Status:

Terminated

Sponsor:


UNC Lineberger Comprehensive Cancer Center

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.